Stock PAB PATRYS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Patrys Limited

Equities

PAB

AU000000PAB9

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:44 2024-04-26 am EDT 		5-day change 1st Jan Change
0.009 AUD 0.00% Intraday chart for Patrys Limited 0.00% +12.50%
Apr. 10 Patrys Reports 'Positive' Results for Deoxymabs in Autoimmune Vasculitis Treatment MT
Feb. 23 Patrys Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 60.87 26.77 12.86 101.7 41.13 20.57
Enterprise Value (EV) 1 54.27 20.3 8.879 90.79 31.31 16.53
P/E ratio -21.5 x -65.1 x -4.68 x -22.2 x -5.78 x -2.91 x
Yield - - - - - -
Capitalization / Revenue 117 x 31.7 x 16.6 x 76 x 12.3 x 7.21 x
EV / Revenue 104 x 24 x 11.5 x 67.8 x 9.39 x 5.8 x
EV / EBITDA -22.2 x -6.04 x -3.29 x -22.6 x -4.65 x -2.36 x
EV / FCF -45.5 x -10.8 x -6.19 x -36.7 x -5.09 x -5.27 x
FCF Yield -2.2% -9.24% -16.2% -2.72% -19.6% -19%
Price to Book 8.35 x 3.67 x 2.64 x 8.44 x 3.06 x 3.01 x
Nbr of stocks (in thousands) 1,067,924 1,070,931 1,071,649 1,816,128 2,056,575 2,057,268
Reference price 2 0.0570 0.0250 0.0120 0.0560 0.0200 0.0100
Announcement Date 8/24/18 8/22/19 8/24/20 8/25/21 8/30/22 8/28/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 0.5205 0.8444 0.7728 1.338 3.334 2.852
EBITDA 1 -2.449 -3.363 -2.701 -4.014 -6.733 -7.015
EBIT 1 -2.497 -3.411 -2.749 -4.063 -6.78 -7.062
Operating Margin -479.76% -404.01% -355.64% -303.57% -203.4% -247.61%
Earnings before Tax (EBT) 1 -2.497 -0.4113 -2.749 -4.063 -6.78 -7.062
Net income 1 -2.497 -0.4113 -2.749 -4.063 -6.78 -7.062
Net margin -479.76% -48.71% -355.64% -303.57% -203.4% -247.61%
EPS 2 -0.002653 -0.000384 -0.002566 -0.002524 -0.003458 -0.003435
Free Cash Flow 1 -1.192 -1.876 -1.435 -2.472 -6.145 -3.135
FCF margin -228.96% -222.22% -185.63% -184.7% -184.35% -109.92%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/24/18 8/22/19 8/24/20 8/25/21 8/30/22 8/28/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 6.61 6.47 3.98 10.9 9.82 4.05
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.19 -1.88 -1.43 -2.47 -6.15 -3.13
ROE (net income / shareholders' equity) -50.2% -5.64% -45.2% -48% -53.2% -69.7%
ROA (Net income/ Total Assets) -28% -26.8% -25.8% -27.8% -31.6% -41.1%
Assets 1 8.906 1.534 10.65 14.61 21.49 17.2
Book Value Per Share 2 0.0100 0.0100 0 0.0100 0.0100 0
Cash Flow per Share 2 0 0.0100 0 0 0 0
Capex 1 0 0 - 0 0 -
Capex / Sales 0.79% 0.48% - 0.29% 0.07% -
Announcement Date 8/24/18 8/22/19 8/24/20 8/25/21 8/30/22 8/28/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PATRYS LIMITED Stock Patrys Limited
+12.50% 12.07M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PAB Stock
  4. Financials Patrys Limited